WO2009025300A1 - イミュノグロブリン結合能を有するペプチド - Google Patents

イミュノグロブリン結合能を有するペプチド Download PDF

Info

Publication number
WO2009025300A1
WO2009025300A1 PCT/JP2008/064837 JP2008064837W WO2009025300A1 WO 2009025300 A1 WO2009025300 A1 WO 2009025300A1 JP 2008064837 W JP2008064837 W JP 2008064837W WO 2009025300 A1 WO2009025300 A1 WO 2009025300A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
binding
peptide
fused protein
peptide capable
Prior art date
Application number
PCT/JP2008/064837
Other languages
English (en)
French (fr)
Inventor
Takahiro Ochi
Toshikazu Shiba
Osamu Masaki
Original Assignee
Regenetiss Inc.
Mmt Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenetiss Inc., Mmt Co., Ltd. filed Critical Regenetiss Inc.
Priority to CN200880112469.7A priority Critical patent/CN101848926B/zh
Priority to US12/733,288 priority patent/US8461299B2/en
Priority to EP08827673.8A priority patent/EP2182003B1/en
Priority to JP2008547804A priority patent/JP4313433B2/ja
Publication of WO2009025300A1 publication Critical patent/WO2009025300A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

　本発明は、イミュノグロブリン結合能を有するペプチドおよびかかるペプチドとの融合タンパク質、それらをコードする核酸、製造方法、イミュノグロブリンを結合させるための組成物および手段、およびイミュノグロブリン結合能を有するペプチドまたはかかるペプチドとの融合タンパク質を含む、Ｃ１ｑとイミュノグロブリンとの結合により引き起こされる疾患の治療または予防用医薬組成物などを提供する。
PCT/JP2008/064837 2007-08-21 2008-08-20 イミュノグロブリン結合能を有するペプチド WO2009025300A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN200880112469.7A CN101848926B (zh) 2007-08-21 2008-08-20 能够结合免疫球蛋白的肽
US12/733,288 US8461299B2 (en) 2007-08-21 2008-08-20 Peptide capable of binding to immunoglobulin
EP08827673.8A EP2182003B1 (en) 2007-08-21 2008-08-20 Peptide capable of binding to immunoglobulin
JP2008547804A JP4313433B2 (ja) 2007-08-21 2008-08-20 イミュノグロブリン結合能を有するペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-214961 2007-08-21
JP2007214961 2007-08-21

Publications (1)

Publication Number Publication Date
WO2009025300A1 true WO2009025300A1 (ja) 2009-02-26

Family

ID=40378199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064837 WO2009025300A1 (ja) 2007-08-21 2008-08-20 イミュノグロブリン結合能を有するペプチド

Country Status (5)

Country Link
US (1) US8461299B2 (ja)
EP (1) EP2182003B1 (ja)
JP (1) JP4313433B2 (ja)
CN (1) CN101848926B (ja)
WO (1) WO2009025300A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084851A1 (ja) * 2009-01-23 2010-07-29 株式会社エム・エム・ティー イミュノグロブリン結合能を有するペプチド
WO2012043397A1 (ja) * 2010-10-01 2012-04-05 株式会社エム・エム・ティー イミュノグロブリン結合能を有するペプチド
JP2015137978A (ja) * 2014-01-23 2015-07-30 シスメックス株式会社 ペプチドの回収方法
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
WO2020027237A1 (ja) * 2018-08-01 2020-02-06 国立大学法人鹿児島大学 ペプチド融合タンパク質
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014029816A1 (en) * 2012-08-22 2014-02-27 Universität Basel Vizerektorat Forschung Anti-c1q epitope elisa
EP3668640A4 (en) * 2017-08-18 2021-07-14 The Johns Hopkins University SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022992A2 (en) * 2001-09-06 2003-03-20 Schering Corporation Mammalian genes; related reagents
WO2008035527A1 (fr) * 2006-09-21 2008-03-27 Mmt Co., Ltd. ANTICORPS MONOCLONAL ANTI-C1q

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260308A (en) * 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US6673561B1 (en) * 1999-06-30 2004-01-06 Regents Of The University Of California Diagnostic test for thrombotic or thromboembolic disease
US20030176328A1 (en) * 2001-12-21 2003-09-18 Maxygen Aps Adiponectin fragments and conjugates
CA2567496A1 (en) * 2004-05-21 2005-12-01 Xencor, Inc. C1q family member proteins with altered immunogenicity
US7749956B2 (en) * 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
WO2007008937A2 (en) 2005-07-11 2007-01-18 Xencor Adiponectin variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022992A2 (en) * 2001-09-06 2003-03-20 Schering Corporation Mammalian genes; related reagents
WO2008035527A1 (fr) * 2006-09-21 2008-03-27 Mmt Co., Ltd. ANTICORPS MONOCLONAL ANTI-C1q

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FREDERICK M. AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS
J. SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", COLD SPRING HARBOR LABORATORY PRESS
OCHI, T. ET AL.: "Natural course of joint destruction and fluctuation of serum Clq levels in patients with rheumatoid arthritis", ARTHRITIS RHEUM., vol. 31, no. 1, 1988, pages 37 - 43, XP003021841 *
See also references of EP2182003A4 *
TRINDER, P.K.E. ET AL.: "Functional definition of a B cell epitope, KGEQGEPGA, on Clq the Fc-binding subunit of the first component of complement.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 50, no. 6, 1999, pages 635 - 641, XP008129801 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383336A1 (en) * 2009-01-23 2011-11-02 Mmt Co., Ltd Peptide capable of binding to immunoglobulin
CN102361979A (zh) * 2009-01-23 2012-02-22 株式会社Mmt 具有免疫球蛋白结合能力的肽
EP2383336A4 (en) * 2009-01-23 2013-01-23 Mmt Co Ltd PEPTIDE CAPABLE OF BINDING TO AN IMMUNOGLOBULIN
CN102942616A (zh) * 2009-01-23 2013-02-27 株式会社Mmt 具有免疫球蛋白结合能力的肽
WO2010084851A1 (ja) * 2009-01-23 2010-07-29 株式会社エム・エム・ティー イミュノグロブリン結合能を有するペプチド
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
WO2012043397A1 (ja) * 2010-10-01 2012-04-05 株式会社エム・エム・ティー イミュノグロブリン結合能を有するペプチド
JP5197887B2 (ja) * 2010-10-01 2013-05-15 株式会社エム・エム・ティー イミュノグロブリン結合能を有するペプチド
CN103237806A (zh) * 2010-10-01 2013-08-07 株式会社Mmt 具有免疫球蛋白结合能力的肽
JP2015137978A (ja) * 2014-01-23 2015-07-30 シスメックス株式会社 ペプチドの回収方法
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
WO2020027237A1 (ja) * 2018-08-01 2020-02-06 国立大学法人鹿児島大学 ペプチド融合タンパク質
CN112469736A (zh) * 2018-08-01 2021-03-09 国立大学法人鹿儿岛大学 肽融合蛋白质
JPWO2020027237A1 (ja) * 2018-08-01 2021-08-02 国立大学法人 鹿児島大学 ペプチド融合タンパク質
JP7202577B2 (ja) 2018-08-01 2023-01-12 国立大学法人 鹿児島大学 ペプチド融合タンパク質
US11643474B2 (en) 2018-08-01 2023-05-09 Kagoshima University Peptide fusion protein

Also Published As

Publication number Publication date
CN101848926A (zh) 2010-09-29
EP2182003A4 (en) 2010-10-06
EP2182003A1 (en) 2010-05-05
JP4313433B2 (ja) 2009-08-12
CN101848926B (zh) 2014-04-30
US8461299B2 (en) 2013-06-11
EP2182003B1 (en) 2014-01-22
US20100167348A1 (en) 2010-07-01
JPWO2009025300A1 (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
WO2007146968A3 (en) Single-chain multivalent binding proteins with effector function
IL210485A (en) An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
WO2013095738A3 (en) Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2009062195A3 (en) Fusion proteins of mannose binding lectins for treatment of disease
IL195191A (en) Digested Proteins, Nucleic Acids Encoded, and the Process of Creating
WO2010010551A3 (en) Angiopoietin derived peptides
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2011020783A3 (en) Targeted immunoconjugates
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2011006915A3 (en) Improved anti-serum albumin binding single variable domains
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
CL2013001124A1 (es) Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo.
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
WO2008054561A3 (en) Proteins, nucleic acids encoding the same and associated methods of use
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2009142460A3 (en) Antibody-peptide fused synergibody
WO2010082804A3 (en) Method for producing physiologically active protein or peptide using immunoglobulin fragment
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880112469.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2008547804

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827673

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008827673

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12733288

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE